Oncology drug development with three drug candidates in renal cell carcinoma, CD30-positive lymphomas, and breast cancer; early clinical development with Phase 1/1b programs.
AI-supported drug discovery
AI-supported drug discovery to identify optimal therapeutic areas for molecules, analyse publicly available life-science data, and accelerate clinical decisions.
Asset licensing and development partnerships
Asset licensing and development partnerships for flexible collaboration with biopharma companies, including financing and de-risked clinical development.
Knowledge
No knowledge articles yet
Once Oncoteq AG has claimed this profile, we'll publish editorial articles and case studies here together.